Unique ID issued by UMIN | UMIN000055075 |
---|---|
Receipt number | R000062907 |
Scientific Title | A systematic review of the antioxidant effects of Astaxanthin on blood lipids |
Date of disclosure of the study information | 2024/07/25 |
Last modified on | 2024/07/25 17:45:07 |
A systematic review of the antioxidant effects of Astaxanthin on blood lipids
A systematic review of the antioxidant effects of Astaxanthin on blood lipids
A systematic review of the antioxidant effects of Astaxanthin on blood lipids
A systematic review of the antioxidant effects of Astaxanthin on blood lipids
Japan |
Healthy adults who were not suffering from any diseases (excluding those under 18, pregnant women, and lactating women)
Not applicable | Adult |
Others
NO
Evaluation of the antioxidant effect of blood lipids by astaxanthin intake.
Efficacy
The primary outcome is inhibition of blood lipid oxidation, especially as an indicator of the oxidation state of blood lipids such as phospholipid hydroperoxide (PLOOH), malondialdehyde (MDA), and isoprostane (ISP)).
Others,meta-analysis etc
18 | years-old | <= |
Not applicable |
Male and Female
A systematic literature search is performed through scientific and clinical trial registries databas
Participants (P): Healthy adults who were not suffering from any diseases (excluding those under 18, pregnant women, and lactating women).
Intervention (I): Intake of foods (tablets, capsules, granules, beverages, processed foods) containing astaxanthin. compositions that also contain ingredients other than Astaxanthin as test substances are excluded.
Astaxanthin intake should be 0.4-30 mg/day.
Comparison (C): The comparison group is set up as consuming a placebo food that does not contain Astaxanthin.
Outcome(O): The primary outcome is inhibition of blood lipid oxidation , especially as an indicator of the oxidation state of blood lipids such as phospholipid hydroperoxide (PLOOH), malondialdehyde (MDA), and isoprostane (ISP)).
Study design (S): Randomized, quasi-randomized, and non-randomized controlled trials (parallel group or crossover controlled trials) will be included.
Studies which do not meet the key inclusion criteria will be excluded.
1st name | Shinobu |
Middle name | |
Last name | Seki |
FUJIFILM Corporation
Consumer Healthcare Business Div.
106-8620
26-30, Nishiazabu 2-chome, Minato-ku, Tokyo, Japan
08013399052
shinobu.seki@fujifilm.com
1st name | Hitomi |
Middle name | |
Last name | Saito |
FUJIFILM Corporation
FUJIFILM Corporation
106-8620
26-30, Nishiazabu 9-chome, Minato-ku, Tokyo, Japan
08021194836
hitomi.saito@fujifilm.com
FUJIFILM Corporation
None
Self funding
Yakujihou Marketing Jimusho Co., Ltd.
N/A
N/A
N/A
None
None
NO
2024 | Year | 07 | Month | 25 | Day |
Unpublished
Preinitiation
2024 | Year | 07 | Month | 25 | Day |
2024 | Year | 07 | Month | 26 | Day |
2025 | Year | 12 | Month | 31 | Day |
This research review will be conducted in accordance with PRISMA2020.
2024 | Year | 07 | Month | 25 | Day |
2024 | Year | 07 | Month | 25 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000062907
Research Plan | |
---|---|
Registered date | File name |
2024/07/25 | 研究プロトコル_アスタキサンチン_血中脂質の抗酸化_240725.pdf |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |